Fractyl Health: Speculative Buy With Binary Risk
Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected in Q3 2025. Current valuation reflects financing and trial risks, but may underappreciate Revita's clinical potential as a durable alternative to GLP-1 drugs. The company's cash runway is critically short, making the REMAIN-1 midpoint data a financial survival catalyst for raising capital on favorable terms.
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Brian Luque - Head of Investor Relations and Corporate Development Harith Rajagopalan - Co Founder and Chief Executive Officer Lisa Davidson - Chief Financial Officer and Treasurer Conference Call Participants Avi Novick - Morgan Stanley Michael DiFiore - Evercore ISI Whitney Ijem - Canaccord Genuity Operator Good afternoon. And welcome to Fractyl Health's First Quarter 2025 Financial Results and Business Updates Call.
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Brian Luque – Head of Investor Relations and Corporate Development Harith Rajagopalan – Chief Executive Officer Lisa Davidson – Chief Financial Officer Conference Call Participants Mike Ulz – Morgan Stanley Michael DiFiore – Evercore ISI William Wood – B. Riley Securities Operator Good afternoon, and welcome to Fractyl Health's Fourth Quarter and Full Year 2024 Financial Results and Business Updates Call.
After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS)
Fractyl Health, Inc. (GUTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-Founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan Stanley Michael DiFiore - Evercore ISI William Wood - B. Riley Securities Operator Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call.
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan Stanley Umer Raffat - Evercore Operator Good afternoon, and welcome to Fractyl Health's Second Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded.
